ImmuneMed, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.immunemed.co.kr
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06306339
- Locations
- 🇳🇱
University Medical Center Urtrecht, Utrecht, GA, Netherlands
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Standard of care
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05808335
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Chung-Ang University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo (intravenous, single dose)Drug: hzVSF-v13 (intravenous, single dose)Drug: hzVSF-v13 (intravenous, multiple dose)Drug: hzVSF-v13 (subcutaneous, single dose)Drug: Placebo (intravenous, multiple dose)Drug: Placebo (subcutaneous, single dose)
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04817202
- Locations
- 🇦🇺
CMAX, Clinical Research Pty Ltd., Adelaide, South Australia, Australia
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04679350
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04679415
- Locations
- 🇮🇩
Rumah Sakit Pasar Minggu, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
🇮🇩Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
🇮🇩Rumah Sakit Umum Persahabatan, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04676971
- Locations
- 🇷🇺
Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Russian Federation
🇷🇺Central City Hospital of Novoshakhtinsk, Novoshakhtinsk, Russian Federation
🇷🇺SPb SBIH "Municipal Hospital №40", Petersburg, Russian Federation
Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03653208
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of